Ngm Biopharmaceuticals Inc Revenue Growth Rates (NGM), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Ngm Biopharmaceuticals Inc   (NASDAQ: NGM)
 

NGM's Revenue Growth by Quarter and Year

Ngm Biopharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NGM Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December 0.17
3rd Quarter September 0.58
2nd Quarter June 1.42
1st Quarter March 2.25
FY 4.42

NGMs Annual Revenue
Ngm Biopharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 4.42 millions
Ngm Biopharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 55.33 millions
Ngm Biopharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 77.88 millions
Ngm Biopharmaceuticals Inc 's Revenue in the fiscal year 2020 $ 87.37 millions
Ngm Biopharmaceuticals Inc 's Revenue in the fiscal year 2019 $ 103.54 millions




NGM Revenue fourth quarter 2023 Y/Y Growth Comment
Ngm Biopharmaceuticals Inc reported drop in Revenue in the fourth quarter 2023 by -99.09% to $ 0.17 millions, from the same quarter in 2022.
The fall in the fourth quarter 2023 Ngm Biopharmaceuticals Inc 's Revenue compares unfavorably to the Company's average Revenue decline of -32.47%.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 81 other companies have achieved higher Revenue growth. While Ngm Biopharmaceuticals Inc ' s Revenue meltdown of -99.09% ranks overall at the positon no. 1732 in the fourth quarter 2023.


NGM Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December -99.09 % -13.26 % 6.02 % -36.39 %
3rd Quarter September -92.67 % -57.43 % -20.87 % 8.85 %
2nd Quarter June -82.87 % -50.57 % -15.13 % -22.02 %
1st Quarter March -89.26 % -2.92 % -11.41 % -4.66 %
FY   -92.02 % -28.96 % -10.85 % -

Financial Statements
Ngm Biopharmaceuticals Inc 's fourth quarter 2023 Revenue $ 0.17 millions NGM's Income Statement
Ngm Biopharmaceuticals Inc 's fourth quarter 2022 Revenue $ 18.18 millions Quarterly NGM's Income Statement


NGM Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December -71.55 % 129.84 % 12.81 % -15.8 %
3rd Quarter September -59.15 % -4.58 % 10.79 % 18.83 %
2nd Quarter June -36.89 % -60.43 % -22.29 % -18.88 %
1st Quarter March -87.62 % -0.05 % 9.16 % -21.62 %
FY (Year on Year)   -92.02 % -28.96 % -10.85 % -


Back to NGM Growth rate Comparisons >> Back to NGM Growth rate Comparisons >>


Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #82
Healthcare Sector #238
Overall #1732

Revenue Y/Y Growth Statistics
High Average Low
-8.66 % -32.47 % -92.02 %
(Mar 31 2022)   (Dec 31 2023)
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #82
Healthcare Sector #238
Overall #1732
Revenue Y/Y Growth Statistics
High Average Low
-8.66 % -32.47 % -92.02 %
(Mar 31 2022)   (Dec 31 2023)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Ngm Biopharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
129.82 % -4.15 % -87.64 %
(Dec 31 2022)  


NGM's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2023 Ngm Biopharmaceuticals Inc disclosed fall in Revenue from the third quarter by -71.55% to $ 0.17 millions, from $ 0.58 millions achived in the previous reporting period.

Although periodic circumstance commonly energize IV. Quarter 2023 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 251 other companies have achieved higher Revenue quarter on quarter growth. While Ngm Biopharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 4061.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #252
Healthcare Sector #653
Overall #4061
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #252
Healthcare Sector #653
Overall #4061
Revenue Q/Q Growth Statistics
High Average Low
129.82 % -4.15 % -87.64 %
(Dec 31 2022)  


NGM's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2023 Ngm Biopharmaceuticals Inc disclosed fall in Revenue from the third quarter by -71.55% to $ 0.17 millions, from $ 0.58 millions achived in the previous reporting period.

Although periodic circumstance commonly energize IV. Quarter 2023 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 251 other companies have achieved higher Revenue quarter on quarter growth. While Ngm Biopharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 4061.


Ngm Biopharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)
Cumulative Revenue 12 Months Ending $ 4.42 $ 22.43 $ 29.76 $ 36.63 $ 55.33
Y / Y Revenue Growth (TTM) -92.02 % -61.4 % -56.73 % -52.58 % -28.95 %
Year on Year Revenue Growth Overall Ranking # 3633 # 1345 # 1520 # 2525 # 2356
Seqeuential Revenue Change (TTM) -80.31 % -24.63 % -18.75 % -33.8 % -4.78 %
Seq. Revenue Growth (TTM) Overall Ranking # 2707 # 1268 # 1464 # 2598 # 1946


Cumulative Revenue growth Comment
Ngm Biopharmaceuticals Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -92.02% year on year, at Dec 31 2023 compare to the -61.4% decrease at Sep 30 2023. If the Ngm Biopharmaceuticals Inc 's fiscal year would end at Dec 31 2023, annual Revenue would be $4 millions.

In the Healthcare sector 493 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1345 to 3633.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 146
Healthcare Sector # 494
Overall # 3633

Revenue TTM Y/Y Growth Statistics
High Average Low
-8.66 %
 -32.47 %
-92.02 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 146
Sector # 403
S&P 500 # 2707
Cumulative Revenue growth Comment
Ngm Biopharmaceuticals Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -92.02% year on year, at Dec 31 2023 compare to the -61.4% decrease at Sep 30 2023. If the Ngm Biopharmaceuticals Inc 's fiscal year would end at Dec 31 2023, annual Revenue would be $4 millions.

In the Healthcare sector 493 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1345 to 3633.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 146
Healthcare Sector # 494
Overall # 3633

Revenue TTM Y/Y Growth Statistics
High Average Low
-8.66 %
-32.47 %
-92.02 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 146
Sector # 403
S&P 500 # 2707




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NGM's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2023
Healthcare Services Group Inc -0.04%$ -0.042 millions
Integra Lifesciences Holdings Corp-0.25%$ -0.247 millions
Nrc Health-0.37%$ -0.375 millions
Skinhealth Systems Inc -0.63%$ -0.633 millions
3m Company-0.82%$ -0.817 millions
Enhabit Inc -0.95%$ -0.950 millions
Viatris Inc -1.00%$ -0.998 millions
Aspira Women s Health inc -1.07%$ -1.068 millions
Supernus Pharmaceuticals inc -1.80%$ -1.801 millions
Opko Health Inc -1.85%$ -1.853 millions
Quest Diagnostics Inc-1.93%$ -1.929 millions
Koru Medical Systems Inc -2.16%$ -2.161 millions
Envista Holdings Corporation-2.30%$ -2.300 millions
Ideaya Biosciences Inc -2.46%$ -2.461 millions
Zynex inc -3.11%$ -3.114 millions
Shl Telemedicine Ltd-3.26%$ -3.259 millions
Pediatrix Medical Group Inc -3.39%$ -3.386 millions
Baxter International Inc -3.55%$ -3.550 millions
Caribou Biosciences Inc -3.63%$ -3.629 millions
Gilead Sciences Inc -3.72%$ -3.722 millions
Lifevantage Corp-3.92%$ -3.921 millions
Avantor Inc -4.02%$ -4.022 millions
Sensus Healthcare Inc -4.11%$ -4.106 millions
Outset Medical Inc -4.17%$ -4.168 millions
Journey Medical Corp-4.44%$ -4.441 millions
Escalon Medical Corp -4.53%$ -4.533 millions
Waters Corporation-4.55%$ -4.547 millions
Inovio Pharmaceuticals Inc -4.55%$ -4.553 millions
Biolase Inc -4.68%$ -4.683 millions
American Shared Hospital Services-4.73%$ -4.725 millions


About Ngm Biopharmaceuticals Inc Revenue Growth Rates (NGM), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Ngm Biopharmaceuticals Inc (CIK 1426332).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-24-010232
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Ngm Biopharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.